Characteristics and outcomes of people with gout hospitalized due to COVID-19: data from the COVID19 Global Rheumatology Alliance physician-reported registry

Research output: Contribution to journalArticlepeer-review


Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized, and characterize their outcomes.
Methods: Data on patients with gout hospitalized for COVID-19 between March 12th, 2020 and October 25th, 2021 were extracted from the COVID-19 Global Rheumatology Alliance (C19-GRA) registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures and COVID-19 outcomes including oxygenation or ventilation support and death.
Results: One hundred and sixty three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years and 85% were male. The majority of the group lived in Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%) and obesity (23%) being the most common. Glucocorticoids and colchicine were used in 11% and 12% of the cohort respectively. Over two-thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.
Conclusion: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support, and death. This suggests that patients with gout hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risks for poor outcomes such as age and presence of comorbidity.

Bibliographical metadata

Original languageEnglish
JournalACR Open Rheumatology
Publication statusAccepted/In press - 25 Jul 2022